An Open, Multineutral Study Evaluating the Safety and Efficacy of CM326 in the Long-term Treatment of Adult Subjects With Atopic Dermatitis
Latest Information Update: 03 Aug 2023
At a glance
- Drugs CM 326 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors KeyMed Biosciences
Most Recent Events
- 28 Jul 2023 Status changed from not yet recruiting to recruiting.
- 05 Jan 2023 New trial record